Andrew Adler

Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome

Barbara L. Cool, Bradley A. Zinker, William J. Chiou et al. · Cell Metabolism · 2006 · 918 citations · Full text

Medicine, Biochemistry, Pharmacology +14

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

John R. Petrie, Nish Chaturvedi, Ian Ford et al. · The Lancet Diabetes & Endocrinology · 2017 · 347 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +14

Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

Terry J. Opgenorth, Andrew Adler, Samuel V. Calzadilla et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 210 citations

Medicine, Pharmacology, Physiology +15

Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats

Daniel J. Kramer, Robin Shapiro, Andrew Adler et al. · Metabolism · 2001 · 99 citations

Medicine, Pharmacology, Physiology +16

Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: <i>ex vivo</i> and <i>in vivo</i> studies

Jerry L. Wessale, Andrew Adler, Eugene I. Novosad et al. · Clinical Science · 2002 · 61 citations

Medicine, Pharmacokinetics, Pharmacology +10